Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor

Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor

Isabella Orienti,1 Giovanna Farruggia,1 Ferro Nguyen,2 Peng Guan,2 Natalia Calonghi,1 Venkatadri Kolla,2 Michael Chorny,2 Garrett M Brodeur2 1Department of Pharmacy and Biotechnology, University of Bologna, Bologna 40127, Italy; 2Divisions of Oncology and Cardiology, Children’s Hospital of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Orienti I, Farruggia G, Nguyen F, Guan P, Calonghi N, Kolla V, Chorny M, Brodeur GM
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
nanomicelles
fenretinide-lenalidomide combination
neuroblastoma
antitumor activity
nanomicelle penetration in tumor cells
gd2 increased expression.
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/df3a503fee734988935e74500c20ab27
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:df3a503fee734988935e74500c20ab27
record_format dspace
spelling oai:doaj.org-article:df3a503fee734988935e74500c20ab272021-12-02T10:36:51ZNanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor1178-2013https://doaj.org/article/df3a503fee734988935e74500c20ab272020-09-01T00:00:00Zhttps://www.dovepress.com/nanomicellar-lenalidomidendashfenretinide-combination-suppresses-tumor-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Isabella Orienti,1 Giovanna Farruggia,1 Ferro Nguyen,2 Peng Guan,2 Natalia Calonghi,1 Venkatadri Kolla,2 Michael Chorny,2 Garrett M Brodeur2 1Department of Pharmacy and Biotechnology, University of Bologna, Bologna 40127, Italy; 2Divisions of Oncology and Cardiology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USACorrespondence: Isabella Orienti Email isabella.orienti@unibo.itPurpose: In a previous study, we demonstrated that the combination of fenretinide with lenalidomide, administered by a novel nanomicellar formulation (FLM), provided a strong antitumor effect in a neuroblastoma TrkB-expressing tumor. In this study, we tested the nanomicellar combination in an MYCN amplified neuroblastoma xenograft to assess its efficacy in different tumor genotypes and evaluate the interactions of the nanomicelles with the tumor cells.Experimental Design: FLM was administered to mice bearing human NLF xenografts to evaluate its efficacy in comparison with the nanomicelles containing fenretinide alone (FM). Confocal laser-scanning fluorescence microscopy images of the NLF cells treated with FLM and FM allowed us to estimate the nanomicelle ability to transport the encapsulated drugs inside the tumor cells. Flow cytometric analysis of the cells from treated tumors was performed to assess the effect of treatment on GD2 expression and NK cell infiltration.Results: FLM and FM decreased the growth of NLF xenografts at comparable extents during the treatment period. Afterwards, FLM induced a progressive tumor regression without regrowth, while FM treatment was followed by regrowth within 15– 20 days after the end of treatment. Both FLM and FM were able to penetrate the tumor cells transporting the encapsulated drugs. FLM transported higher amount of fenretinide inside the cells. Also, FLM treatment strongly increased GD2 expression in treated tumors and slightly decreased the NK infiltration compared to FM.Conclusion: FLM treatment induced a superior antitumor response than FM in NLF xenografts, presumably due to the combined effects of fenretinide cytotoxicity and lenalidomide antiangiogenic activity. The ability of FLM to penetrate tumor cells, transporting the encapsulated drugs, substantially improved the therapeutic efficiency of this system. Moreover, the enhancement of GD2 expression in FLM treated tumors offers the possibility to further increase the antitumor effect by the use of anti-GD2 CAR-T cells and anti-GD2 antibodies in combination with FLM in multimodal therapies.Keywords: nanomicelles, fenretinide–lenalidomide combination, neuroblastoma, antitumor activity, nanomicelle penetration in tumor cells, GD2 increased expression.Orienti IFarruggia GNguyen FGuan PCalonghi NKolla VChorny MBrodeur GMDove Medical Pressarticlenanomicellesfenretinide-lenalidomide combinationneuroblastomaantitumor activitynanomicelle penetration in tumor cellsgd2 increased expression.Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 6873-6886 (2020)
institution DOAJ
collection DOAJ
language EN
topic nanomicelles
fenretinide-lenalidomide combination
neuroblastoma
antitumor activity
nanomicelle penetration in tumor cells
gd2 increased expression.
Medicine (General)
R5-920
spellingShingle nanomicelles
fenretinide-lenalidomide combination
neuroblastoma
antitumor activity
nanomicelle penetration in tumor cells
gd2 increased expression.
Medicine (General)
R5-920
Orienti I
Farruggia G
Nguyen F
Guan P
Calonghi N
Kolla V
Chorny M
Brodeur GM
Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
description Isabella Orienti,1 Giovanna Farruggia,1 Ferro Nguyen,2 Peng Guan,2 Natalia Calonghi,1 Venkatadri Kolla,2 Michael Chorny,2 Garrett M Brodeur2 1Department of Pharmacy and Biotechnology, University of Bologna, Bologna 40127, Italy; 2Divisions of Oncology and Cardiology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USACorrespondence: Isabella Orienti Email isabella.orienti@unibo.itPurpose: In a previous study, we demonstrated that the combination of fenretinide with lenalidomide, administered by a novel nanomicellar formulation (FLM), provided a strong antitumor effect in a neuroblastoma TrkB-expressing tumor. In this study, we tested the nanomicellar combination in an MYCN amplified neuroblastoma xenograft to assess its efficacy in different tumor genotypes and evaluate the interactions of the nanomicelles with the tumor cells.Experimental Design: FLM was administered to mice bearing human NLF xenografts to evaluate its efficacy in comparison with the nanomicelles containing fenretinide alone (FM). Confocal laser-scanning fluorescence microscopy images of the NLF cells treated with FLM and FM allowed us to estimate the nanomicelle ability to transport the encapsulated drugs inside the tumor cells. Flow cytometric analysis of the cells from treated tumors was performed to assess the effect of treatment on GD2 expression and NK cell infiltration.Results: FLM and FM decreased the growth of NLF xenografts at comparable extents during the treatment period. Afterwards, FLM induced a progressive tumor regression without regrowth, while FM treatment was followed by regrowth within 15– 20 days after the end of treatment. Both FLM and FM were able to penetrate the tumor cells transporting the encapsulated drugs. FLM transported higher amount of fenretinide inside the cells. Also, FLM treatment strongly increased GD2 expression in treated tumors and slightly decreased the NK infiltration compared to FM.Conclusion: FLM treatment induced a superior antitumor response than FM in NLF xenografts, presumably due to the combined effects of fenretinide cytotoxicity and lenalidomide antiangiogenic activity. The ability of FLM to penetrate tumor cells, transporting the encapsulated drugs, substantially improved the therapeutic efficiency of this system. Moreover, the enhancement of GD2 expression in FLM treated tumors offers the possibility to further increase the antitumor effect by the use of anti-GD2 CAR-T cells and anti-GD2 antibodies in combination with FLM in multimodal therapies.Keywords: nanomicelles, fenretinide–lenalidomide combination, neuroblastoma, antitumor activity, nanomicelle penetration in tumor cells, GD2 increased expression.
format article
author Orienti I
Farruggia G
Nguyen F
Guan P
Calonghi N
Kolla V
Chorny M
Brodeur GM
author_facet Orienti I
Farruggia G
Nguyen F
Guan P
Calonghi N
Kolla V
Chorny M
Brodeur GM
author_sort Orienti I
title Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
title_short Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
title_full Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
title_fullStr Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
title_full_unstemmed Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
title_sort nanomicellar lenalidomide–fenretinide combination suppresses tumor growth in an mycn amplified neuroblastoma tumor
publisher Dove Medical Press
publishDate 2020
url https://doaj.org/article/df3a503fee734988935e74500c20ab27
work_keys_str_mv AT orientii nanomicellarlenalidomidendashfenretinidecombinationsuppressestumorgrowthinanmycnamplifiedneuroblastomatumor
AT farruggiag nanomicellarlenalidomidendashfenretinidecombinationsuppressestumorgrowthinanmycnamplifiedneuroblastomatumor
AT nguyenf nanomicellarlenalidomidendashfenretinidecombinationsuppressestumorgrowthinanmycnamplifiedneuroblastomatumor
AT guanp nanomicellarlenalidomidendashfenretinidecombinationsuppressestumorgrowthinanmycnamplifiedneuroblastomatumor
AT calonghin nanomicellarlenalidomidendashfenretinidecombinationsuppressestumorgrowthinanmycnamplifiedneuroblastomatumor
AT kollav nanomicellarlenalidomidendashfenretinidecombinationsuppressestumorgrowthinanmycnamplifiedneuroblastomatumor
AT chornym nanomicellarlenalidomidendashfenretinidecombinationsuppressestumorgrowthinanmycnamplifiedneuroblastomatumor
AT brodeurgm nanomicellarlenalidomidendashfenretinidecombinationsuppressestumorgrowthinanmycnamplifiedneuroblastomatumor
_version_ 1718396971596644352

Ejemplares similares